- Familiar intravesical
instillation - Administered in your urology office once
every
3 months - Monotherapy requiring no Bacillus Calmette-
Guérin (BCG) coadministration - No reconstitution or dilution required
Dosing
ADSTILADRIN Is the
Most Conveniently
Dosed Instillation for
High-Risk NMIBC
Discover treatment that integrates seamlessly into your patients’ schedules and your urology practice
DOSING BENEFITS
For your practice1
Simplified dosing that reduces
the treatment burden
For your patients1,2
Effective, well-tolerated treatment
after BCG failure
- Chemo free and nonsystemic
- Minimally invasive and device free
- Well-tolerated safety profile
- Quarterly maintenance may continue
as long as patients respond
ADSTILADRIN
is the only NMIBC
treatment with
quarterly dosing1,3-6
)
ADSTILADRIN is provided in a carton containing
4 vials1
- Each vial has an extractable volume of 20 mL. All vials have a nominal concentration of 3 x 1011 vp/mL
- A dose of 75 mL of ADSTILADRIN is administered through a urinary catheter
- Premedication with an anticholinergic prior to each instillation
is recommended - No reconstitution is necessary, and no hood is required for handling
- After instillation, have the patient retain ADSTILADRIN in the bladder for the entire 1-hour dwell time, repositioning approximately every 15 minutes
ADSTILADRIN in Practice
Neal Shore, MD, FACS, a clinician from the ADSTILADRIN clinical trials, shares important information about implementing ADSTILADRIN in your office.
Dosing Comparison Leave Behind Download
Compare the dosing differences between ADSTILADRIN and existing non–muscle-invasive bladder cancer treatments with this helpful resource
Instructions for Use Download
A summary of storage, preparation, administration,
and disposal information
for ADSTILADRIN
Sign Up to Receive Information and Updates on ADSTILADRIN (nadofaragene firadenovec-vncg)
Form ToggleReferences: 1. ADSTILADRIN. Package insert. Ferring Pharmaceuticals, Inc; August 2024. 2. Narayan VM, Boorjian SA, Alemozaffar M, et al. Efficacy of intravesical nadofaragene firadenovec for patients with Bacillus Calmette-Guérin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial. J Urol. 2024;212(1):1-12. doi:10.1097/JU.0000000000004020 3. Keytruda. Prescribing information. Merck & Co, Inc; 2024. 4. Anktiva. Prescribing information. ImmunityBio, Inc; 2024. 5. Patel SH, Gabrielson A, Collins C, et al. Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive urothelial carcinoma of the bladder: updates from a phase 2 trial. J Clin Oncol. 2023;41(suppl 6):507. doi:10.1200/JCO.2023.41.6_suppl.507 6. TICE BCG. Package insert. Merck & Co, Inc; 2022.
Important Safety Information
INDICATION
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.
WARNINGS AND PRECAUTIONS:
- Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
- Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.
DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.
USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.
ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).
You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.
Please see full Prescribing Information for ADSTILADRIN.